secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106525
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics Q2 revenue $26.8M (+6% YoY); net income falls to $1.6M; CEO transition
--------------------------------------------------------------------------------

- GAAP net income of $1.6M ($0.00 EPS) vs $4.5M in Q2 2024; H1 net income $5.3M vs $14.5M.
- Revenue Q2 $26.8M, up from $25.2M; H1 $48.8M, down from $52.4M due to ETUARY decline and new product launches.
- Full-year revenue guidance reaffirmed at $118-128M (11-21% growth). Non-GAAP adj. net income Q2 $2.9M vs $3.1M.
- CEO Han Ying resigned, becomes SVP Science; Executive Chair Ping Zhang appointed interim CEO.
- Pipeline: Positive Phase 3 Hydronidone data; NDA filing with NMPA expected Q3 2025. Launched Etorel in June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/0000950170-25-106525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer